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1. Introduction
1.1. Melanoma — Background
In  the  United  States,  skin  cancer  is  the  most  common type  of  cancer,  which  is  further
divided  into  three  types  of  cancer:  basal  cell,  squamous  cell  and  melanoma.  Basal  cell
and squamous cell  cancers are the most common types of skin cancer,  but they are less
deadly  and  more  readily  treated  than  melanoma.  While  it  is  the  least  common  of  the
skin cancers,  more than 68,000 Americans are diagnosed with melanoma each year,  and
an additional 48,000 are diagnosed with early forms of cancer that involve the top layer
of the skin. [1] It is the leading cause of death from skin cancer, due to its metastatic be‐
havior. The frequency of melanoma has more than doubled in the past thirty years, espe‐
cially in Western industrialized societies. [2]
Melanoma is a malignant tumor that originates in the melanocytes. Melanocytes are found
randomly throughout the basal cells and are found in the deepest portions of the epidermis.
They are responsible for making the pigments (melanin) found in the skin. The level of pigment
released by melanocytes is directly related to skin color. It has been found that exposure to
ultraviolet radiation triggers the melanocytes to create more pigments, which leads to what
we observe as tanned skin. Studies show that melanoma has different, common locations of
occurrence in men and women. [1] Men have been found to commonly develop melanoma on
the skin of the head, neck, between the shoulders and the hips, whereas women often develop
melanoma on the skin of the lower legs or between the shoulders or hips. Melanoma can occur
on any skin surface, but it is more prone to develop on preexisting moles. There are five stages
of melanoma [1]; Stage 0; Melanoma is only located in the top layer of the skin and the basil
lamina is intact. This is referred to as melanoma in situ, Stage I; the melanoma lies in the
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epidermis. The tumor is no more than 1 mm thick and has penetrated the basil lamina and
extended into the papillary dermis, Stage II; The tumor is between 1 and 2 mm thick and
extends into the papillary-reticular dermis interface, Stage III; The tumor extends into the
reticular dermis and the melanoma cells have spread into at least one lymph node or to nearby
tissues, and Stage IV; The cancer cells have metastasized to the lungs or other organs, skin
areas, or lymph nodes far from the original growth. The tumor has also extended into the
subcutaneous fat. Detecting melanoma early is crucial to the survival rate of the patient.
2. Risk factors for melanoma
There are several risk factors attributed to the development of melanoma in individuals.
Exposure to ultraviolet radiation has been shown to be a major risk factor in the development
of melanoma. Severe sunburns increase the likelihood of developing melanoma later in one’s
life. Although tanning decreases the likelihood of sunburns, it is not a method of counteracting
cancer, for it increases the duration of sun exposure. In addition, individuals with fair skin or
who are prone to severe, blistering sunburns are at a high risk of developing melanoma.
Melanoma is far less common in dark skinned individuals. In addition, the duration of sun
exposure over one’s life is a factor in the risk of radiation induced melanoma. A person who
has lived most of his/her life in an area of high sun exposure is more likely to develop
melanoma. Similarly, people who live in higher altitudes, where the sun is stronger, are at a
greater risk for developing melanoma than those who live at lower altitudes. Another risk
factor is personal history of melanoma. An individual who has been diagnosed with melanoma
before is likely to contract another form of melanoma. In addition, someone who has been
diagnosed with basal cell or squamous cell skin cancer is at a high risk of developing another
form of skin cancer, including melanoma. Family history of the disease is also a contributing
factor. Individuals who have ancestral cases of melanoma are at a high risk of developing the
disease themselves. The risk of developing melanoma is increased when the family incidences
are in one’s immediate family. Approximately 8-12% of cases of cutaneous melanoma are
inherited. [3]
3. Current treatment regimens for melanoma
There are several existing treatments for melanoma, including surgery, chemotherapy [4],
radiation therapy [5], biological therapy [6], and to a lesser extent, photodynamic therapy.
These treatments can be used in any combination to varying degrees of success. Since mela‐
noma is typically a more invasive form of skin cancer, many of these treatments act as
deterrents rather than cures. However, if the melanoma is diagnosed and treated early enough,
it can be cured with a high degree of success.
The primary treatment for melanoma is surgery. In the surgical process, the tumor is excised
along with some of the surrounding healthy tissue so that there is a minimal chance of leaving
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cancer cells in the area. Chemotherapy is another fairly common procedure for treating
melanoma. Chemotherapy is a type of cancer treatment that relies on drugs in order to stop
or slow the growth of cancer cells. However, chemotherapy indiscriminately harms healthy
cells that also grow rapidly, such as those located in the mouth, intestines, and hair. The
effectiveness of chemotherapy relies on the type and severity of the cancer in question, and
depending on the aforementioned factors, it can cure, control, or ease cancer. Chemotherapy
can be administered alone, but it is typically used in conjunction with other cancer treatments,
such as biological therapy, radiation therapy, or surgery. The treatment can be administered
in a variety of ways: injection, intra-arterial, intraperitoneal, intravenous, topical, or oral. The
therapy sessions are spread out so that there is a recovery period in between treatments.
Radiation therapy is another type of therapy used in the treatment of melanoma. Like
chemotherapy, radiation therapy can cure, stop, or slow cancer growth depending on the type
and severity of the disease. Also similar to chemotherapy, radiation therapy is indiscriminate
in its treatment, affecting nearby healthy cells in addition to the afflicted cells. Radiation
therapy employs radiation to kill cancer cells, and this radiation can be administered either
internally or externally. Because internal radiation therapy places the radiation source inside
the body, it allows for a more precise treatment of the cancer in question than external beam
treatment. Radiation therapy also possesses serious side effects, many of which can be more
severe if chemotherapy is received in addition to radiation therapy. The most common side
effects include fatigue and skin changes such as dryness, itching, peeling, or blistering.
Biological therapy is also used as a cancer treatment. Biological therapy, like chemotherapy,
relies on drugs in order to combat cancer. However, biological therapy differs from chemo‐
therapy because it aids the immune system in fighting cancer. Like many of the other treat‐
ments, biological therapy can be used to stop or slow growth, and it makes it easier for the
immune system to destroy cancer cells.
Although it has been around for over three decades and has been successfully used to treat
other forms of skin cancer, photodynamic therapy (PDT) has not received as much attention
especially in the United States as a treatment option for melanoma. The major reason for this
lack of attention stems from the fact that PDT requires visible light of specific wavelengths to
be effective; however, the pigments found particularly in melanoma block this light making
PDT less effective. As will be described in this chapter, researchers are looking at innovative
ways to develop PDT into a useful treatment option for melanoma.
4. Photodynamic Therapy (PDT)
4.1. Discovery and applications
Photodynamic therapy (PDT),  the therapeutic use of  light,  was first  discovered by Raab
[7] when he reported that the combination of acridine orange and light could destroy liv‐
ing organisms. In the 1920’s it  was noted by Policard [8] that the effects of fluorescence
were inherently more for  tumor tissue than the healthy tissue.  A great  deal  of  research
has been done on PDT, which represents an interesting treatment modality for numerous
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health  related  conditions,  especially  but  not  limited  to  cancer  treatment.  It  is  now  be‐
lieved that PDT also treats immunological effects (new antibiotics) [9], inflammation [10]
and bacterial infections. [11]
Traditional cancer treatment includes radiation, surgery and/or chemotherapy, all of which
have deleterious side effects. As an alternative to these treatments PDT offers a more targeted
and less invasive treatment regimen. Until now, photodynamic therapy has been used for
treatment of bladder cancers, brain cancers, breast metastases, skin cancers, gynecological
malignancies, colorectal cancers, thoracic malignancies, and oral, head and neck cancers. [12]
Although it is not completely understood, researchers have reported that PDT activates and
suppresses the immune system, [13] by a combination of effects that begins after the light
treatment, the curative properties arise from the death of the irradiated cancer cells. The
damage to the plasma membrane and membrane of the cellular organelles by singlet oxygen
can trigger other events with far reaching consequences. The mechanism by which PDT
induces specific immune responses has been suggested by Korbelik. [14] Summarizing, PDT-
treated tissue release large quantities of cell debris, and inflammatory signals, cytokines and
chemo-tactic agents which trigger the tissue to secrete immunosuppressive factors. The work
of Musser [15] showed that PDT-induced immune suppression was also a function of the
photosensitizer used.
Another PDT-induced effect is inflammation. It is reported that vascular destruction, observed
after PDT is similar to the inflammatory response after tissue injury or bacterial infection. [16]
This process is characterized by the release of a wide range of potent mediators including
vasoactive substances, components of clotting cascades, proteinases, peroxidases, radicals,
leucocytes, chemoattractants, cytokines, growth factors, and other immunoregulators.
5. Mechanisms of action for PDT
PDT typically utilizes a photosensitizer, molecular oxygen and light to destroy cancer cells.
Two mechanisms [17] of the actions for PDT are recognized, Fig 1. In anoxic environments,
the light induced excitation of the photosensitizer can promote an electron to a higher energy
state. At this point a variety of reactions can take place. For example, this excited photosensi‐
tizer can react directly with organic substrates by electron exchange, filling the hole vacated
by the excited electron, producing an oxidized substrate and reduced photosensitizer.
Guanine, the most susceptible base to oxidation, is the presumed target leading to the
formation of various oxo-guanine complexes and ultimately the decomposition of cellular
DNA. [18] The reduced photosensitizer can react with oxygen to produce superoxide anions
(O2-) which can then form the highly reactive hydroxyl radical (OH•). The excited photosen‐
sitizer can also react with superoxide radicals (O2•) to produce superoxide anions (O2-) which
can then create the highly reactive hydroxyl radical (OH•). Collectively these reactions are
classified as Type-I photoreactions and are characterized by a dependence on the target-
substrate concentration, Fig 2.
Recent Advances in the Biology, Therapy and Management of Melanoma256
 Type I 
Type II 
superoxide 
 
3O2 
O2• − 
1O2 
D 
P0 
P1* 
P2* 
A 
Molecular Oxygen Photosensitizer 
B 
D 
C 
E 
F G 
hν 
3O2 
Figure 1. A diagram shows the various energy and electron transfer during PDT: (A) excitation; (B) fluorescence; (C)
intersystem crossing; (D) electron transfer; (E) phosphorescence; (F) internal conversion; (G) non-radiated transfer of
energy to singlet oxygen. P0 is the ground state of photosensitizer, P1* and P2* are the excited state of photosensitizer,
3O2 is the triplet ground state oxygen, 1O2 is the singlet excited state oxygen
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Figure 2. Type-I and type-II photoreactions, where 1P is a photosensitizer in a singlet ground state, 3P* is a photosensi‐
tizer in a triplet excited state, S is a substrate molecule, P- is reduced photosensitizer molecule, S+ is an oxidized sub‐
strate molecule, O2 is molecule oxygen (triplet ground state), O2- is the superoxide anion, 3O2 is triplet ground-state
oxygen, 1O2 is singlet excited state, and S(O) is an oxygen adduct of a substrate.
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The second mechanism also involves excitation of the photosensitizer with light but in this
mechanism energy is transferred to the ground state of molecular oxygen resulting in excited
singlet oxygen which goes on to destroy cellular function. [19] It was first identified that the
cyto-toxic product of the photochemical reaction for PDT to be singlet oxygen by Weishaupt
et al. in 1976. [20] The photosensitizer and oxygen interact through the triplet states because
oxygen has a unique, triplet-ground state and low-lying excited states. The energy required
for the triplet to singlet transition in oxygen is 22 kcal mol-1 which corresponds to the energy
of a wavelength of 1274 nm (infrared light). [21] The energy needed to produce singlet oxygen
is relatively low. Photochemical reactions of this type are known as Type-II photoreactions
and are characterized by a dependence on oxygen concentration, Fig 2. [22] It is believed that
the Type-II mechanism dominates during PDT. [23]
6. Photosensitizers
6.1. Development of photosensitizers and photofrin
Numerous attempts were made to treat tumor tissue with photosensitizing agents since the
potential of photo treatment was discovered. Before the 1960s, scientists applied natural
macrocycles to patients and tumor-bearing animals in an attempt to more accurately detect
tumor tissue by florescence. [24-27] During the 1960s, Schwartz isolated a tumor localizing
impurity from hematoporphyrin preparations that was later named hematoporphyrin
derivative (HpD), Fig 3. Meanwhile, Lipson was investigating how to detect tumor tissue by
fluorescence of hematoporphyrin. Unable to obtain reproducible results with hematopor‐
phyrin, Lipson began experimenting with Schwartz’s HpD. He used it as a tumor detection
agent, [28] and first recognized that it could work as a photosensitizer to destroy tumor tissue.
[29] In the 1970s, Dougherty’s group discovered that fluorescein diacetate could photody‐
namically destroy TA-3 cells in vitro [30] and found that it could be used as a photosensitizer.
[31] Following that, the group of Weishaupt identified that the cytotoxic product of photody‐
namic reaction to be singlet oxygen. [13] However, fluorescein has a low singlet oxygen
quantum yield and a long wavelength absorption in the green portion of the electromagnetic
spectrum that does not penetrate deeply into tissue. Macrocyclic photosensitizers were then
examined as photosensitizers because they are efficient singlet oxygen generators and have
absorption maxima in the red portion of the electromagnetic spectrum.
Eventually, Schwartz’s Hpd was rediscovered by Dougherty, which by then was known to
have a high singlet oxygen quantum yield, an absorption maximum in the red, and is selec‐
tively retained in tumor tissues. [30] After several years spent isolating and identifying the
active fractions of HpD, a purified version named Photofrin@, was approved for use in the
United States against early- and late-stage lung cancers and esophageal cancers and dyspla‐
sia with other indications pending. [30] This drug upon photoexcitation in the visible region
(red) of the spectrum generates singlet oxygen from triplet oxygen through energy transfer
(type II mechanism) resulting in cell death. [31]
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This chapter will focus on macrocycles (porphyrins and phthalocyanines) as potential
photosensitizers for the treatment of melanoma by photodynamic therapy. There are a number
of reviews of porphyrin and phthalocyanine photosensitizers and their use as PDT agents for
a variety of cancers. [32-41]
7. Porphyrin Photosensitizers
7.1. Porphyrin background
Porphyrins have been extensively studied as potential photosensitizers in photodynamic
therapy (PDT). [42]- [45] Their planar aromatic structure coupled with their photophysical
properties and synthetic versatility has made them attractive components for PDT. [46]
Although synthetic routes toward porphyrins leads to relatively low yields, their starting
materials are typically inexpensive and their synthesis is generally straightforward, as
illustrated for the porphyrin synthesis of meso-tetrapyridylporphyrin, Fig. 4. The synthesis
typically requires reaction of pyrrole with the aldehyde of choice to give the appropriate
substitution at the meso-positions. The meso-positions are indicated in Fig. 4 by the numbers 5,
10, 15, 20. Purification by column chromatography gives the desired porphyrin. As illustrated
in the electronic spectra of Fig. 4 porphyrins display a very intense Soret band at approximately
410 nm and four lower energy Q-bands. The lowest energy Q-band, with absorptivities in the
tens of thousands, at approximately 650 nm is the transition of interest for PDT. In addition,
porphyrins have been associated with high affinity for tumor sites and efficient formation of
ROS. [47] Specifically, cationic porphyrins have been studied primarily for their water
solubility and their strong electrostatic interactions with negatively charged phosphate oxygen
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atoms of the DNA backbone. [48] This section will focus on studies, performed in the past
decade, involving porphyrins as photosensitizers for the treatment of melanoma.
Figure 4. Synthesis and electronic spectra of meso-tetrapyridylporphyrin (H2TPP).
8. Porphyrins, PDT and melanoma
In 1999 Busetti, Soncin and coworkers studied the effects of PDT on melanoma tumors in mice.
[49] The inefficiency of Photofrin to treat highly pigmented melanoma has been related to the
absorption of the wavelengths of light necessary to activate Photofrin by the melanin in the
tumors. For this reason Busetti and coworkers chose a benzoporphyrin derivative monoacid
ring A (BPD-MA), verteporfin, trade name visudyne, Fig. 5. Verteporfin has been used to
eliminate abnormal blood vessels in the eye associated with macular degeneration.
Figure 5. Structure of verteporfin.
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The studies were conducted on C57/BL6 mice implanted with heavily pigmented melanoma
B16. Injection of the photosensitizer, 5.5 μmol/kg body weight, was allowed 3 h for a maximum
concentration to be reached in the cells. The researchers noted limited selectivity of BPD-MA
toward tumor cells and adjacent tissue. The majority of the BPD-MA was cleared through the
bile-gut pathway within 24 h of injection, with small amounts found in the liver. Irradiation
of the tumors involved an argon-pump dye laser at 690 nm, within the photodynamic window
of 600-800 nm. Three hours after injection of the photosensitizer the tumors were irradiated
with energy of 520 mJ cm-2. Large necrotic areas of the tumor were observed at this time as
well as reduction in tumor growth. The researchers noted that mice implanted with B16 tumors
and irradiated after injection of the photosensitizer were tumor free for up to two weeks after
treatment. The phototoxicity observed for BPD-MA treated mice was not observed in tumors
irradiated in the absence of the photosensitizer.
In a subsequent study researchers investigated a porphyrin dimer as a potential PDT agent for
the treatment of melanoma. The dimer, 10, 15, 20-tritolylporphyrin-5-(4-amidophenyl)-[5-(4-
phenyl)-10, 15, 20-tritolyporphyrin] (T-D), Fig. 6, was synthesized by the Adler method of
refluxing mixed aromatic aldehydes with pyrrole in propionic acid. [50] The dimer (T-D) was
synthesized from the monomeric porphyrin units by a known literature method.
Figure 6. Structure of 10, 15, 20-tritolylporphyrin-5-(4-amidophenyl)-[5-(4-phenyl)-10, 15, 20-tritolyporphyrin] (T-D)
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The electronic spectra of the dimer displayed an intense Soret band at 423 nm with less intense
Q-bands at 517, 552, 592, and 649 nm in organic solvents. Photoexcitation for PDT treatment
focused on the 649 band, although its molar absorptivity was relatively low (7550 M-1 cm-1).
Singlet oxygen generation for the excited dimer gave a very high quantum yield of 0.8. Due to
the complexes insolubility in aqueous buffer solutions the dimer was dissolved in dimethyl
sulfoxide (DMSO) and diluted to 10-8 to 10-5 M concentrations in aqueous phosphate buffer for
the cell studies.
Photodynamic experiments were performed on human (SKMEL 188) melanoma cells and
mouse (S91) melanoma cells. The melanoma cells were incubated with various concentrations
of the T-D solutions for 24 h before irradiation. Melanoma cells incubated with 10-7 M T-D
phosphate buffer solutions were irradiated with an LH313K lamp filtered to cut off wave‐
lengths below 630 nm. Energy doses between 13.5 and 82 J cm-2 were used with irradiation
times of 30 min. Cells were incubated for 36 h after irradiation before determining cell death.
Both human and mouse melanoma cells showed a 3-fold decrease in size compared to cells
irradiated without T-D at 81 J cm-2. Although the dimer is insoluble in aqueous solutions and
requires high energy irradiation for phototoxicity the authors point out that this complex has
some distinct advantages over Photofrin for the treatment of pigmented melanoma, namely,
chemical homogeneity, low aggregation (which can lead to excited state quenching), and good
solubility in hydrophobic base with relatively long-lived triplet excited states, leading to
significant singlet oxygen production.
9. Halogenated porphyrins
Synthetically enhancing porphyrins as PDT agents has been achieved through incorporation
of halogens into the porphyrin structure. [51-54] Halogens covalently bound to phenyl groups
at the meso-positions promote intersystem crossing, increasing singlet oxygen production; for
example, halogenated tetraaryl porphyrins combined through a diarylethyne linker (where
the halogens are chloro and fluoro substituted phenyl groups), Fig 7, had significantly longer
excited state lifetimes when compared to their non-halogenated analogs. [51]
In addition, PDT agents with fluorophenyl substituents have been efficiently converted to
porphyrin-saccharide conjugates to enhance their uptake in cancer cells, while in a separate
study water soluble fluorinated porphyrins have shown more efficient PDT activity than their
non-fluorinated counterparts. [53,54]
Researchers in 2007 looked at a water soluble porphyrin incorporating chloro groups. [55]
The porphyrin, 5, 10, 15, 20-tetrakis-(2-chloro-3-sulfophenyl)porphyrin (TCPPSO3H), Fig. 8,
was synthesized by reacting 2-chlorobenzaldeyde with pyrrole by the method of Adler and
Longo, followed by sulfonation. The electronic spectrum of the complex is typical of por‐
phyrins with an intense Soret band and four lower energy lower intensity Q-bands. The
lowest energy Q-band at 633 nm displayed a molar absorptivity of 504 M-1cm-1 in aqueous
pH 7 phosphate buffer. Singlet oxygen quantum yields were determined to be 0.74, signifi‐
cantly higher than the non-halogenated analog.
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Figure 7. Structures of the halogenated tetraaryl porphyrins combined through a diarylethyne linker.
Figure 8. Structure of 5, 10, 15, 20-tetrakis-(2-chloro-3-sulfophenyl)porphyrin (TCPPSO3H).
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The melanoma cells studied were mouse (S91) and human (SKEML 188). At concentrations of
TCPPSO3H of 2 x 10-4 M or greater dark toxicity in S91 melanoma cells was observed. The S91
melanoma cells were determined to be more sensitive to the photosensitizer in the dark than
the human SKMEL 188 cells; therefore, concentrations of 2 x 10-5 M buffered solutions of
TCPPSO3H were used for PDT experiments on both cell lines. Cellular uptake of TCPPSO3H
buffered solutions reached a peak after two hours with the S91 cells being five times greater
than the SKMEL 188 cells. Thirty minute irradiation with 4 J cm-2 or higher led to 90% cell
toxicity for both types of cells. S91 cells were still dead 24 h post PDT treatment with 20 μM
TCPPSO3H and 6.2 J cm-2 light doses.
In a more recent study halogenated porphyrin photosensitizers were studied as PDT agents,
Fig. 9, against A375 melanoma cells. [56] It has been noted that halogenated structures can
interfere with the activity of P-glycoprotein (P-gp). This can enhance drug therapy by pre‐
venting the function of the P-gp to eliminate these drugs from the cells. Complexes 2-5, Fig.
9, (the halogenated porphyrins) led to the highest quantum yields for singlet oxygen formation
compared to the non-halogenated complex, 1 Fig. 9. Photobleaching after 24 h of irradiation
was minimal for complexes 1-5. In addition, no dark toxicity was observed for the complexes
in the presence of melanoma cells.
Figure 9. Structure of halogenated porphyrins.
For the PDT experiments melanoma cells were incubated for 24 h with concentrations of
complexes 1-5 ranging from 50 nM to 10 μM. Irradiation of the cells after incubation with the
complexes, performed with 10 J cm-2, was evaluated 24 h post PDT treatment. Surprisingly, all
of the complexes, including the non-halogenated photosensitizer, showed thirty times the
efficiency for photokilling than Photofrin against A375 melanoma cells; however, no appreci‐
able difference was noted between the halogenated and non-halogenated complexes. Further
studies are needed to determine the effect of the halogenated porphyrins on P-gp inhibition.
Apart from production of singlet oxygen another mechanism of PDT action, as stated earlier,
is the formation of reactive oxygen species (ROS) within the cell. ROS, for example, hydrogen
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peroxide, hydroxyl radicals, or superoxide anions are highly reactive leading to oxidative
damage of cellular biomolecules. Cells are equipped with enzymes capable of counter acting
a limited amount of ROS; however, PDT can lead to an overproduction of ROS which cellular
mechanisms are unable to handle. To this end, researchers have synthesized and investigated
a series of water soluble porphyrins containing Zn(II), Pd(II) metal centers, as well as, the free-
base porphyrin. [57] The sulfonated porphyrin analogs of meso-tetrakis-(4-sulfonatophen‐
yl)porphyrin (TPPS4) are illustrated in Fig. 10. Fluorescence probes were used to determine
the production of hydrogen peroxide after PDT treatment in human melanoma (G361) cells.
Production of hydrogen peroxide by PDT leads, through a series of reactions, to the formation
of hydroxyl radicals, the most reactive and deadly form of ROS. The photosensitizers in this
study were noted to be homogeneously distributed throughout the cells, excluding the
nucleus. The most effective of the photosensitizers in this study was the Zn(II)TPPS4 complex,
generating the highest concentration of ROS in the melanoma cells (G361) at 100 μM concen‐
trations and light doses of 5 J cm-2; however, the optimal concentration leading to photocyto‐
toxicity was determined to be 10 μM. Cell viability was linked to light dose, photosensitizer
concentration, and the type of photosensitizer.
Figure 10. Structure of meso-tetrakis-(4-sulfonatophenyl)porphyrin (TPPS4)
In a unique application, researchers have combined PDT with boron neutron capture therapy
(BNCT). [58] The porphyrin photosensitizer in this study was appended with 36 boron atoms,
meso-tetra-(4-nido-carboranylphenyl)porphyrin (H2TCP), as illustrated in Fig. 11.
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Figure 11. Structure of meso-tetra-(4-nido-carboranylphenyl)porphyrin (H2TCP).
As a PDT agent H2TCP was measured to generate singlet oxygen in aqueous solutions with a
quantum yield of 0.44. Boron neutron capture therapy (BNCT) is used for cancer treatment by
injection of a non-toxic radio-sensitizing agent. Irradiation of 10B-enriched tumor lesions with
low energy neutrons results in the release of highly toxic 4He2+ and 7Li3+ causing severe damage
to biological molecules and eventually leading to cell death. Like PDT, BNCT is a targeted
treatment modality which the authors anticipated could be used in a synergistic fashion to
give maximum tumor killing with minimal collateral damage to healthy cells.
For this study pigmented melanoma (B16F1) cells were subcutaneously transplanted into mice
through injection. After seven days tumors were measured at 0.6 cm in diameter, at this point
treatment was initiated. The photosensitizer H2TCP showed no photobleaching after 20 min
irradiation indicating its stability under these conditions. The appropriate solution for PDT
treatment was obtained when H2TCP was dissolved in 20% dimethylsulfoxide – 30% polye‐
thyleneglycol – 50% water. Distribution of the photosensitizer was observed in melanoma cells
after 24 h incubation. Irradiation with 600-700 nm light for 10 min led to complete cell death
at 20 μM concentrations of H2TCP. There was no dark toxicity toward the melanoma cells at
concentrations as high as 50 μM H2TCP. Fluorescence experiments of the cell studies suggest
that the predominant pathway to cell death was necrotic. Mouse studies indicated that
injections of H2TCP of 5 μg/kg were almost completely eliminated from the plasma within 3
h post injection. In addition, maximum tumor accumulation of the photosensitizer was
achieved at 3 h post injection with little change after 24 h. Unfortunately poor tumor selectivity
was also observed with equal amounts of the photosensitizer being recovered from the skin
as well as the tumor tissue. Before PDT and BNCT studies are conducted the authors feel it is
important to further investigate other methods of photosensitizer transport to enhance its
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localization in the tumor cells. This complex does offer the hope of a combined targeted therapy
for the treatment of melanoma.
10. Ruthenium complexes and ruthenated porphyrins
Although Photofrin@ was approved by U.S. Food and Drug Administration (FDA) for use in
the United States, it suffers from dark toxicity and purification difficulties. In order to overcome
these, another class of compounds which have received a great deal of attention as potential
PDT agents are ruthenium complexes containing polypyridyl ligands. [59-62] For example,
excitation of the Metal to Ligand Charge Transfer (MLCT) state of a Ru(II) polypyridyl
complex, Fig 12, has been shown to lead to the formation of ROS resulting in efficient cleavage
of supercoiled DNA. [63] The Ru(II) polypyridyl complexes have intense, overlapping MLCT
transitions in the visible region of the spectrum for acceptor ligand and ligand-based π→π*
transitions in the UV region. The complexes efficiently absorb light throughout the UV and
visible allowing for efficient excitation. The MLCT emissions of these Ru complexes are
quenched by oxygen to produce 1O2.
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Figure 12. DNA photocleavage agents [(TL)2Ru(dpp)]Cl2 with TL = 2,20-bipyridine (bpy), 1,10-phenanthroline (phen)
or 4,7-diphenyl- 1,10-phenanthroline (Ph2phen), with the polyazine bridging ligand 2,3-bis(2-pyridyl)pyrazine (dpp).
Ruthenium complexes coordinated to the periphery of porphyrin molecules have also been
shown to interact with DNA. [64-71] In one study a mono-ruthenated porphyrin, Fig 13, caused
single strand breaks of circular plasmid DNA when irradiated with UV light. It was suggested
that the mechanism of photocleavage was related to the formation of radical cations of guanine.
[66] A separate study of a tetra-ruthenated porphyrin, Fig 13, suggested electrostatic binding
to DNA and photocleavage of circular plasmid DNA through formation of singlet oxygen. [69]
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Figure 13. The structure of the mono-ruthenated porphyrin: [MPyTPPARu(pip)2Cl]+ and the structure of tetra-ruthen‐
ated porphyrin: μ-{meso-5,10,15,20-tetra(4-pyridyl)porphyrin}- tetrakis-{bis-(bipyridine)chlororuthenium(II)}4+.
11. Melanoma and ruthenium porphyrins
Reactions of Ru(η6-arene)(μ-Cl) complexes with 5, 10, 15, 20-(4-pyridyl)porphyrin (TPP) in
refluxing methanol gave tetranuclear ruthenium porphyrins in excellent yield, Fig. 14. [72]
Figure 14. Structures of ruthenated tetraphenyl porphyrins.
The complexes in this study were used to investigate growth inhibition of human Me300
melanoma cells. The melanoma cells were incubated with various concentrations of complexes
1-5 over a 24 h period. Cell survival was determined by accepted protocol (MTT assay). Dark
toxicity experiments revealed that complexes 3 and 4 were moderately toxic while complexes
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1, 2, and 5 were less toxic to the cells. Localization of complex 2 in the cells cytoplasm was
determined by fluorescence measurements; however, nuclear localization was not observed.
Melanoma cells incubated with 10 μM concentrations of complexes 1-5 for 24 h were irradiated
using a red laser at 652 nm, with a light dosage range of 5-30 J cm-2. After irradiation 24 h was
allowed to lapse before cell cytotoxicity was measured. In the absence of the photosensitizers,
1-5, irradiation of the melanoma cells was determined to be ineffective at cell killing. Light
doses as low as 5 J cm-2 in the presence of the complexes indicated 60-80% melanoma cell killing.
Little difference in phototoxicity was observed for the complexes after PDT treatment under
the same conditions. Therrien and coworkers have studied a variety of interesting ruthenium
substituted porphyrin photosensitizers for their effects as PDT agents against pigmented
melanoma. [73-75]
In an attempt to combine the tumor affinity of porphyrins with the enhanced excited state
lifetimes afforded by halogens and the added benefits of coordinated ruthenium polyazine
groups we have investigated the synergistic effects of these substituents as PDT agents for the
treatment of melanoma. [76,77] In our most recent study we synthesized a series of ruthenated
pyridyl porphyrins containing one pentafluorophenyl group at the meso-position combined
with a series of transition metal ions, Fig. 15. [77]
Figure 15. Transition metal and free base ruthenium porphyrin analogs.
Early experiments of the free base porphyrin showed extraordinary ability to photocleave
circular plasmid DNA when irradiated with light above 400 nm. When various transition metal
ions (Ni(II), Cu(II), and Zn(II)) were inserted into the porphyrin the photocleavage ability was
markedly reduced. Cell studies were performed on human dermal skin fibroblast cells and
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malignant melanoma cells obtained from a 53 year old male. Normal and melanoma cells were
incubated for 24 h at 37 ºC in the dark with complex concentrations of 5 and 10 μM. The
complexes (I-IV) did not show any dark toxicity toward either normal fibroblast or melanoma
cells. PDT experiments were performed by irradiating the cultured cells (containing the
photosensitizers) for either 30 or 60 min intervals with a 60 W tungsten lamp. In the case of
the free base porphyrin (I) irradiation of 30 min at concentrations as low as 3 μM indicated
complete cell killing of both normal fibroblast and melanoma cells. In contrast, irradiation
times of 60 min at concentrations of the Ni(II) and Cu(II) complexes (II and III) of 10 μM showed
no cell damage for either the normal fibroblast or melanoma cells. The Zn(II) complex (IV)
showed the greatest potential as a PDT agent. Irradiation for 30 min at concentrations of the
Zn(II) porphyrin of 5 and 10 μM showed minimal cell damage of the normal fibroblast cells
but induced complete cell killing of the melanoma cells. Further studies are needed to
determine the effect of the central metal ions on the phototoxicity of these complexes.
12. Phthalocyanine photosensitizers – Background
Phthalocyanines represent another form of macrocyle, similar in many ways to porphyrins.
Synthetic routes to phthalocyanines vary; however, one common method involves reacting o-
cyanobenzamide with phthalimide to give the tetrabenzoporphyrazin, more commonly
named, phthalocyanince (Pc), Fig. 16.
Figure 16. Synthesis of phthalocyanine.
Phthalocyanines have the ability, like porphyrins, to coordinate metal ions within their
nitrogen core, they are a tetradentate ligand. This has offered numerous ways to synthetically
alter their physical properties. If not at the metal center, substitutions of Pc’s is typically made
at the benzo-periphery (positions 1-4, 8-11, 15-18, and 22-25, Fig. 16). Two advantages Pc’s
seem to have over porphyrins, as potential PDT agents, is their comparatively high yields and
their spectroscopic properties. Like porphyrins, Pc’s have a Soret band at higher energy ca.
400 nm and Q-bands at lower energy; however, in the case of Pc’s the low energy Q-bands
(650-750 nm) are typically much more intense than the Soret bands, opposite of porphyrins.
These intense absorptions fit very nicely within the photodynamic window needed for PDT.
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One major drawback is that Pc’s lack the specificity toward tumor cells that porphyrins possess,
this has led to numerous synthetic manipulations to try and find ways to get the Pc’s into the
tumor.
13. Phthalocyanines, PDT and melanoma
Researchers in 1999 compared Photofrin (HpD), Zn(II) phthalocyanine (ZnPc), Zn(II) naph‐
thalocyanine (ZnNc), and a newly synthesized tetrabenzamido-substituted Zn(II) phthalo‐
cyanine (ZnNcA) as PDT agents against B16 pigmented melanoma. Pathogen-free male
C57B1/6 mice between 6 and 8 weeks of age were transplanted with 1 mm3 pieces of melanoma
tumor tissue. Six days post-transplant, tumor diameters were between 3 and 4 mm, at this
point PDT treatment was initiated. [78] Tumor infected mice were injected with the photo‐
sensitizers and irradiated 24 h after injection with wavelengths between 630-780 nm. Twenty
one days after PDT treatment HpD and ZnPc treated mice showed no effect on the tumors.
Some tumor growth delay was observed 15 days post PDT treatment with the ZnNc photo‐
sensitizer. Higher photosensitizer concentrations and increased irradiation energy did not
produce increased phototherapeutic effects for these photosensitizers. In the case of the ZnNcA
photosensitizer treated mice pronounced tumor necrosis post irradiation was observed with
tumor diameters held at 4 mm up to 19 days after treatment. ZnNcA shows singlet oxygen
generation quantum yields of 0.33 with good accumulation in the tumor which has been linked
to its success against these particular tumors.
Aggregation is a common issue with macrocyclic complexes. To address this two new
silicon(IV) centered phthalocyanines have been synthesized, Fig. 17. [79]
Both  of  the  complexes  in  Fig.  17  have  electronic  spectra  displaying  intense  Q-bands  at
668 nm. In this study M6 achromic melanoma cells were incubated with the desired pho‐
tosensitizer  for  1  h prior  to irradiation.  Irradiation experiments involved a 250 W tung‐
sten-halogen  lamp  containing  a  filter  to  cut  off  wavelengths  below  480  nm.  After  the
cells  were irradiated they were washed with PBS buffer solutions and grown in a fresh
culture for 6 h. Due to low water solubility of HexSiPc, this photosensitizer was incorpo‐
rated in EYL (egg yolk lecithin) lisosomes. Under these conditions the maximum concen‐
tration of Cl2SiPc in M6 cells was 2.18 ng and 15.3 ng for HexSiPc, obtained after 90 min
of  incubation.  No  evidence  of  dark  toxicity  was  observed  for  concentrations  of  Cl2SiPc
between 10-10  and 10-8  M or for concentrations of HexSiPc between 10-10  and 10-5  M. The
Cl2SiPc complex showed little  M6 killing after  1  h of  incubation and 20 min irradiation
with  a  250  W tungsten-halogen  lamp.  The  HexSiPc  photosensitizer,  on  the  other  hand,
(entrapped in EYL) gave LD90 of 3 x 10-7 M after 20 min of irradiation and 2 x 10-9 M af‐
ter 2 h of irradiation with a 250 W tungsten-halogen lamp. It was concluded that the su‐
perior photokilling observed for HexSiPc was linked to lipid peroxidation.
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Figure 17. Structure of (Cl2SiPc) and (HexSiPc).
Another study aimed at decreasing Pc aggregation while increasing its lipophilicity included
a series of SiPc complexes containing various substituents coordinated to the silicon metal
center, one of which is illustrated in Fig. 18. [80]
Figure 18. Structure of bis(cholesteryloxy) derivative of SiPc.
This study involved human pigmented melanoma cells SKMEL-2. The photosensitizers were
dissolved in tetrahydrofuran (THF) and entrapped in liposomes to increase tumor affinity.
Irradiation experiments were performed using a 250 W tungsten-halogen lamp filtered to cut
off wavelengths below 480 nm. The melanoma cells were incubated with the substituted SiPc
liposome entrapped complexes prior to irradiation for 20 min. Of the six Si-substituted Pc’s in
this study the best photokilling was observed for the complex illustrated in Fig. 18. Photokilling
efficacy of Chol-O-SiPc, in vitro, was seven to nine times greater than the known reference
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chloro-aluminum phthalocyanine with LD50 = 6-8 x 10-9 M. The mechanism of photokilling of
this complex was evaluated by kinetic studies indicating that faster mitochondrial mediated
apoptosis was occurring by PDT with this complex as compared to the reference Pc.
As noted earlier generation of ROS leads to cell death and blood vessel damage; crucial to
tumor regression. In a study of G361 human melanoma cells with a disulfonated chloroalu‐
minum phthalocyanine (ClAlPcS2) photosensitizer, researchers were interested in looking at
the generation of ROS and hydrogen peroxide after PDT treatment. The complex, ClAlPcS2,
was made water soluble by conversion to its ammonia salt. [81] The electronic spectra of this
complex displayed an intense Q-band at 670 nm. PDT experiments were performed by
irradiation with a semiconductor laser at 675 nm and energies of 10 and 20 J cm-2. At lower
light doses of energy (10 J cm-2) and higher concentrations of Pc, 7.5 and 75 μg/mL, increased
generation of ROS was observed; however, at light doses of 20 J cm-2 and concentrations of Pc
of 0.75 μg/mL larger amounts of ROS were generated as compared to higher concentrations
and higher light doses. The most ROS generated were at a concentration of 75 μg/mL and light
dose of 10 J cm-2. G361 melanoma cell viability studies indicated that the optimal phototoxicity
could be obtained with a light dose of 25 J cm-2 and concentrations of photosensitizer of 5 μg/
mL and 10 μg/mL.
Phthalocyanines, like porphyrins, have also been combined with boron isotopes in an attempt
to obtain a synergistic treatment method involving PDT and BNCT (boron neutron capture
therapy). The ZnPc coupled to boron, in this study, is illustrated in Fig. 19. [82]
Figure 19. Structure of ZnB4Pc.
Due to low water solubility the ZnB4Pc complex was incorporated into liposomes. The complex
was stable for one week in liposomal aqueous suspensions. The photosensitizer-liposome
suspension was used to study B16F1 melanotic melanoma cells. After 18 h of incubation with
the melanoma cells the peak concentration of ZnB4Pc complex obtained was 7 μm, with no
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dark toxicity observed. Red light irradiation of B16F1 cells incubated for 1 h with 7 μM
ZnB4Pc-liposomes resulted in > 95% cell death. No regrowth of melanotic melanoma cells after
several days post-irradiation was observed.
Pigmented melanoma cells were transplanted into C57BL/6 mice subcutaneously. The best
results for PDT treatment of melanoma transplanted mice after injection of ZnB4Pc was
observed with irradiation 3 h post injection with wavelengths between 600-700 nm. PDT
experiments conducted 24 and 48 h post injection were ineffective in shrinking the tumors,
leading the authors to conclude that the PDT treatment was affecting the blood vessels
associated with the tumor. Moreover, significant tumor growth delay was observed when
BNCT treatment was conducted 24 h post injection of the ZnB4Pc complex suggesting that this
complex offers a dual pathway toward melanoma treatment.
Various synthetic routes have been taken to reduce aggregation of phthalocyanines while
increasing their water solubility. A recent study looked at coordination of N-methylated
piperazine substituents at the axial positions of a silicon(IV) phthalocyanine. [83] N-methyla‐
tion lends a cationic charge to the complex making it water soluble while the bulky Si-
coordinated substituents prevent aggregation, Fig. 20.
Figure 20. Structure of bis(4-(4-acetylpiperazine)phenoxy)phthalocyanoto silicon(IV) N-methyl derivative.
Suprisingly, this structurally complicated phthalocyanine was synthesized with a yield of 73%.
Electronic absorption spectra of the complex reveals an intense Q-band at 685 nm in N,N-
dimethylformamide (DMF). In aqueous solution the Q-band shifts to lower energy, 690 nm,
while obeying the Beer-Lambert law, indicating no aggregation at the concentrations studied.
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Investigations of singlet oxygen production gave a quantum yield of 0.49. To enhance
biocompatibility and selectivity the phthalocyanine was complexed with bovine serum
albumin (BSA), a common protein carrier for anticancer drugs. Studies were conducted on B16
melanoma cells using 0.1 μM concentrations of photosensitizer. At this concentration no dark
toxicity was observed. PDT treatment was conducted with red light greater than 610 nm at 60
J cm-2 resulting in complete killing of the B16 melanoma cells.
There are a limited number of studies in which phthalocyanines have been combined with
ruthenium complexes for the purpose of PDT. Researchers in 2009 synthesized a Tb(III)
phthalocyanine capable of hydrogen bonding to a polypyridyl Ru(II) complex in aqueous
solution, Fig. 21. [84] The idea was to incorporate the photosensitizing ability of the phthalo‐
cyanine to generate singlet oxygen under oxygen rich conditions, when irradiated with low
energy light and photolytic release of nitric oxide from the ruthenium complex under hypoxic
conditions. This would give dual capabilities for photodynamic damage since nitric oxide has
been linked to antitumor activity.
Figure 21. Structure of cis-[Ru(H-dcbpy-)2(Cl)(NO)][Na4(Tb(TsPc)(acac)]
Although the complex was not isolated it was assumed to form hydrogen bonds in aqueous
solution. The electronic spectrum of a one to one mixture of the complexes in aqueous solution
reveals two intense absorption bands at 642 nm and 682 nm. PDT studies were performed on
B16F10 pigmented murine melanoma cells. When irradiated at 691 nm the quantum yield for
singlet oxygen production was measured to be 0.41. Some dark toxicity was observed;
however, upon irradiation, 80% of the melanoma cells had undergone photocytotoxicity. In
the absence of the phthalocyanine there was reduced cell viability which was linked to the
release of nitric oxide upon irradiation of the ruthenium complex.
Studies have indicated that nanoparticles enhance tumor targeting. To take advantage of this
property researchers have combined phthalocyanines with gold nanoparticles dispersed in an
emulsion, Fig. 22. Electronic spectra of the free C11Pc and C11Pc-Np display an intense Q-band
at 696 nm. [85]
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Figure 22. Structure of C11Pc.
Mice (C57) transplanted with B78H1 amelonotic clone of murine melanoma were used in this
study. At 10 to 15 days post melanoma transplantation (tumor external diameters of 0.4 to 0.6
cm) the C11Pc and C11Pc-Np emulsions were injected at a dose of 1.5 μmol/kg body weight.
The highest accumulation of photosensitizer found in the tumor was observed at 24 h post
injection, while at 3 h post injection significant amounts of photosensitizer was found in the
serum. Irradiation studies were performed at 3 h and 24 h post injection with wavelengths of
light between 600 nm and 700 nm. It was noted that untreated mice died within 3 weeks of
melanoma transplant. Suprisingly, little effect on tumor growth was observed when tumors
were irradiated 24 after photosensitizer injection, when the photosensitizer was at a maximum
concentration within the tumor. However, irradiation 3 h post injection led to significant tumor
growth delay for both C11Pc and C11Pc-Np. The authors indicate that the observed growth
delay was most likely due to vascular damage to the tumor cells leading to low blood flow to
the cells.
14. Other macrocycles for PDT of melanoma and concluding remarks
We would be remiss if we did not acknowledge the great deal of research devoted to photo‐
sensitizer macrocycles other than porphyrins and phthalocyanines for the treatment of
melanoma. Although this chapter has focused primarily on porphyrins and phthalocyanines
there are other similar complexes under investigation as PDT agents for melanoma. One of the
more promising photosensitizers being studied is based on the macrocycle texaphyrin. The
lutetium texaphyrin in this study, Fig. 23, showed water solubility and intense absorbance
between 700 nm and 760 nm. [86]
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Figure 23. Structure of Lu-texaphyrin (PCI-0123).
PCI-0123 was studied in C57BL/6 mice transplanted with the pigmented murine melanoma
B16F10. PDT studies of the tumor transplanted mice injected with PCI-0123 irradiated with
732 nm light showed delay in tumor growth and increased life spans. The interested reader is
encouraged to review the following references for further information on other macrocycles
being studied as PDT agents for the treatment of melanoma. [87-93]
It is clear that a great deal of research is ongoing toward finding new PDT agents for the
treatment of melanoma. This trend will certainly increase as the incidence of melanoma
continues to increase throughout the world. There are many challenges yet to be overcome;
however, photosensitizers capable of treating melanoma by PDT are continually being
developed. Two major hurdles which must be addressed are, first, overcoming the ability of
pigmented melanoma to absorb wavelengths needed to activate the photosensitizer and
second, the metastatic nature of melanoma. Great strides have been made to develop photo‐
sensitizers capable of phototoxicity in pigmented melanoma. Unfortunately, it is unlikely that
PDT will be a viable option (on its own) for the treatment of advanced stage melanoma which
has begun to metastasize. In combination with traditional melanoma treatments PDT is
becoming a more accepted regimen for the treatment of this most deadly form of skin cancer.
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